Lilly abandons plan to submit arzoxifene for FDA review

08/18/2009 | Wall Street Journal, The · Indianapolis Business Journal

Eli Lilly and Co. said it will not submit its osteoporosis medicine arzoxifene for FDA review after the drug failed to meet certain clinical goals in a Phase III clinical trial. The Indianapolis drug firm will take an after-tax charge of $35 million to $45 million for discontinuing arzoxifene's development.

View Full Article in:

Wall Street Journal, The · Indianapolis Business Journal

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN